Ubs Oconnor LLC Halozyme Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 24,683 shares of HALO stock, worth $1.33 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

24,683

Holding current value

$1.33 Million

% of portfolio

0.1%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $461,700 - $579,780	-9,000 Reduced 26.72%	24,683 $1.41 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $983,060 - $1.36 Million	-26,000 Reduced 43.56%	33,683 $1.76 Million
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $1.08 Million - $1.34 Million	32,000 Added 115.59%	59,683 $2.43 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $1.36 Million - $1.72 Million	-40,860 Reduced 59.61%	27,683 $1.02 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $364,600 - $440,300	-10,000 Reduced 12.73%	68,543 $2.62 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $2.38 Million - $3.04 Million	78,543 New	78,543 $2.83 Billion
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $413,477 - $700,873	12,583 Added 21.95%	69,920 $2.67 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $1.07 Million - $1.58 Million	-26,600 Reduced 31.69%	57,337 $0
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $154,120 - $207,120	-4,000 Reduced 4.55%	83,937 $3.32 Billion
Q2 2022 Aug 12, 2022	BUY	$37.35 - $48.3 $483,196 - $624,857	12,937 Added 17.25%	87,937 $3.87 Million
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $2.4 Million - $3.08 Million	75,000 New	75,000 $2.99 Million

Others Institutions Holding HALO

# of Institutions

536

Shares Held

124M

Call Options Held

177K

Put Options Held

167K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.52B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account